MetaVia Inc. (MTVA): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 08:35 ET
- Event date
- 2026-11-13
- Accession no.
- 0001104659-26-126540
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
MetaVia reports third-quarter results and DA-1726 clinical development update
MetaVia reported a third-quarter net loss of $4.6 million and cash and cash equivalents of $8.8 million as of September 30, 2026. It disclosed DA-1726 interim results and plans for a 48-week Phase 2 study in MetALD and ALD, targeted for the second half of 2027. Full Phase 1 Parts 3A and 3B data are expected in the first quarter of 2027.
- Third-quarter net loss was $4.6 million, or $0.69 per basic and diluted share, compared with $3.4 million a year earlier.
- Cash and cash equivalents was $8.8 million as of September 30, 2026, compared with $10.3 million as of December 31, 2025.
- DA-1726 interim data showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at Day 109.
- Sarah Browne, M.D., was appointed Chief Medical Officer in October 2026.
earningsproductexecutive change
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | mtva-20261113x8k.htm |
| EX-99.1 | EX-99.1 | mtva-ex99d1.htm |
| EX-99.2 | EX-99.2 | mtva-ex99d2.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.